Altimmune to present pemvidutide clinical data at upcoming nash-tag conference january 8, 2022

Gaithersburg, md., jan. 03, 2022 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. scott harris, chief medical officer at altimmune, will give an oral and a poster presentation on pemvidutide, the company's novel, investigational glp-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (nash), the most severe form of non-alcoholic fatty liver disease (nafld). the presentations will take place at the nash-tag conference, which is being held january 6-8, 2022, in park city, utah. details for the oral presentation are as follows:
ALT Ratings Summary
ALT Quant Ranking